News of cancer vaccines proliferate in the media, yet only one such vaccine has been approved - against metastatic prostate cancer - and is no longer in use. However, only one as such has been approved - against metastatic prostate cancer - and it is no longer in use. Are the attention and hopes justified? What do they consist of and how are they similar to traditional ones? Are they preventive or therapeutic? Can they be universal or will they be extremely personalised? How much will they cost? This is what we know today.
Approved therapies to treat various tumours using CAR-T cells are based on the modification of the patient's own lymphocytes in the laboratory, which delays their administration. A phase 1 clinical trial has used ready-made donor cells to treat patients with multiple myeloma. The results are published in the journal Nature Medicine.
Two preclinical studies published in the journal Science have introduced new bioengineered modifications to CAR-T cells in an attempt to make them more potent and safer in their anti-tumour action. These variations allow their activity to be enhanced only in the vicinity of the tumour or their actions to be regulated on demand.
A pioneering phase 1 clinical trial has tested a type of cancer immunotherapy. Researchers have modified patients' own T-lymphocyte receptors using the CRISPR tool to direct them against specific targets on their own tumours. The results are published in the journal Nature.
Research to be published in the journal Nature identifies and characterizes the cells responsible for relapse in colon cancer. In addition, it proposes revising clinical guidelines and administering immunotherapy before surgery to try to avoid them